Sales of its blockbuster drug (Eylea) to combat Macular Degeneration recently eclipsed $5 billion.
- Will its early and end stage pipeline provide additional blockbuster drugs?
It’s stock has declined over 35% from its highs but still trounced the averages over the past 10 years.
- Does the company represent good value at this point? What are the risks to holding Regeneron’s shares?